Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intrathecal Drug Delivery System Clear all
Terminated Phase 1 Interventional

Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I

NCT00215527
View directory record Official record
Conditions
Mucopolysaccharidosis I, Lysosomal Storage Diseases, Spinal Cord Compression
Interventions
laronidase
Drug
Lead sponsor
Patricia I. Dickson, M.D.
Individual
Eligibility
8 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 28, 2026, 1:26 PM EDT
Completed Phase 2 Interventional Results available

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

NCT02385110
View directory record Official record
Conditions
Leukemia
Interventions
Alemtuzumab, Etoposide, Dexamethasone, Methotrexate, Phone Call, Tocilizumab
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 28, 2026, 1:26 PM EDT
Recruiting Not applicable Interventional

Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

NCT05866419
View directory record Official record
Conditions
Spinal Muscular Atrophy, Spine Deformity, Scoliosis
Interventions
ThecaFlex DRx System
Device
Lead sponsor
Alcyone Therapeutics, Inc
Industry
Eligibility
3 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 28, 2026, 1:26 PM EDT
Completed Phase 2 Interventional Results available

Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis

NCT01104025
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
ATG, rabbit, Etoposide, Methotrexate, hydrocortisone, Dexamethasone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 28, 2026, 1:26 PM EDT
Terminated Phase 1 Interventional

Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I

NCT00786968
View directory record Official record
Conditions
Spinal Cord Compression, Mucopolysaccharidosis I, Hurler-Scheie Syndrome, Scheie Syndrome, Lysosomal Storage Disease
Interventions
laronidase
Drug
Lead sponsor
Patricia I. Dickson, M.D.
Individual
Eligibility
8 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 28, 2026, 1:26 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)

NCT04530955
View directory record Official record
Conditions
Injuries, Spinal Cord, CVA (Cerebrovascular Accident), Traumatic Brain Injury, MS (Multiple Sclerosis), Muscle Spasticity, Cerebral Palsy, Spastic
Interventions
Prometra II Programmable Pump - Flowonix Medical
Device
Lead sponsor
Culicchia Neurological Clinic
Other
Eligibility
22 Years to 85 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Marrero, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Oct 28, 2026, 1:26 PM EDT
Not yet recruiting No phase listed Observational

Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy

NCT07499882
View directory record Official record
Conditions
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Interventions
Ziconotide
Drug
Lead sponsor
Christian Hospital Northeast Northwest
Other
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 28, 2026, 1:26 PM EDT
Recruiting Phase 1 Interventional

Intraneural Administration of scAAV9/JeT-GAN Into the Vagus Nerve for Patients With Giant Axonal Neuropathy (GAN)

NCT07543991
View directory record Official record
Conditions
Giant Axonal Neuropathy (GAN)
Interventions
scAAV9/JeT-GAN
Genetic
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
10 Years to 25 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 28, 2026, 1:26 PM EDT
Completed Phase 4 Interventional Results available

Determining the Prognostic Value of Continuous Intrathecal Infusion

NCT03523000
View directory record Official record
Conditions
Lumbar Post-Laminectomy Syndrome, Chronic Low Back Pain, Vertebral Compression Fracture, Failed Back Surgery Syndrome
Interventions
Continuous intrathecal prognostic infusion test, Bupivacaine, Fentanyl, Placebo, Intrathecal Drug Delivery System (IDDS)
Other · Drug · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
30 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 28, 2026, 1:26 PM EDT
Terminated Not applicable Interventional Results available

Intrathecal Morphine Compared to Conventional Medical Management for Pain Control and Opioid-related Side Effects

NCT01924182
View directory record Official record
Conditions
Chronic Pain
Interventions
SynchroMed Infusion System and Intrathecal Morphine Sulfate, Conventional Medicine
Device · Other
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Homewood, Alabama • Napa, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 28, 2026, 1:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Glymphatic Kinetics In Healthy Adult Volunteers

NCT03218111
View directory record Official record
Conditions
Healthy
Interventions
MR Imaging, CT-guidance
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
20 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 28, 2026, 1:26 PM EDT
Completed Phase 2 Interventional Results available

A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy

NCT03771898
View directory record Official record
Conditions
Metachromatic Leukodystrophy (MLD)
Interventions
SHP611
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Months to 72 Months
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
11
States / cities
Torrance, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 28, 2026, 1:26 PM EDT
Completed No phase listed Observational Results available

Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery

NCT01117090
View directory record Official record
Conditions
Cerebral Palsy, Multiple Sclerosis, Traumatic Brain Injury, Spinal Cord Injury
Interventions
Not listed
Lead sponsor
MedtronicNeuro
Industry
Eligibility
12 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Indianapolis, Indiana • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 28, 2026, 1:26 PM EDT
Withdrawn Not applicable Interventional

A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain

NCT02578459
View directory record Official record
Conditions
Pain Management, Cancer Pain
Interventions
Intrathecal Drug Delivery System, Conventional Medical Management
Device · Other
Lead sponsor
Flowonix Medical
Industry
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 28, 2026, 1:26 PM EDT
Completed Phase 1 Interventional

Melphalan in Patients With Neoplastic Meningitis

NCT00002750
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Leukemia, Lymphoma, Ovarian Cancer
Interventions
melphalan
Drug
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 28, 2026, 1:26 PM EDT
Terminated Phase 2 Interventional Results available

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT03071276
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Selinexor, Fludarabine, Cytarabine, methotrexate/hydrocortisone/cytarabine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Palo Alto, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 22, 2020 · Synced Oct 28, 2026, 1:26 PM EDT
Completed Phase 4 Interventional

Ziconotide as First-Line IDT

NCT03321955
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Ziconotide 100 MCG(microgram)/ML Intrathecal Solution, Quantitative sensory testing, Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factor
Drug · Diagnostic Test
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 28, 2026, 1:26 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)

NCT05394064
View directory record Official record
Conditions
AMN, AMN Gene Mutation, X-ALD
Interventions
SBT101 Treatment
Genetic
Lead sponsor
SwanBio Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 28, 2026, 1:26 PM EDT
Terminated Phase 1 Interventional Results available

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

NCT01887587
View directory record Official record
Conditions
Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia
Interventions
MLN9708, Vincristine, Doxorubicin, Dexamethasone
Drug
Lead sponsor
Ehab L Atallah
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 28, 2026, 1:26 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain

NCT00414466
View directory record Official record
Conditions
Chronic Intractable Pain
Interventions
Intraspinal Gabapentin
Drug
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years to 70 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
14
States / cities
Little Rock, Arkansas • Napa, California • Sarasota, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 28, 2026, 1:26 PM EDT
Completed Phase 1 Interventional

Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

NCT03194932
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Venetoclax, Cytarabine, Idarubicin, Intrathecal Triple Therapy, Azacitidine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 20 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Palo Alto, California • Chapel Hill, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 28, 2026, 1:26 PM EDT
No Longer Available No phase listed Expanded access

ARCHIMEDES Compassionate Use Supplement

NCT00660556
View directory record Official record
Conditions
Pain
Interventions
Archimedes Constant Flow Pump & System
Device
Lead sponsor
Cerenovus, Part of DePuy Synthes Products, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Danville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 28, 2026, 1:26 PM EDT
Completed Not applicable Interventional

Prometra Post-Approval Study

NCT01854229
View directory record Official record
Conditions
Chronic Pain, Cancer Pain, Intractable Pain, Back Pain
Interventions
Prometra Programmable Intrathecal Infusion Pump
Device
Lead sponsor
Flowonix Medical
Industry
Eligibility
22 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
26
States / cities
La Jolla, California • Santa Barbara, California • Santa Rosa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 28, 2026, 1:26 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment

NCT02055118
View directory record Official record
Conditions
Hunter Syndrome
Interventions
idursulfase-IT, No IT treatment
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
Up to 18 Years · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Oakland, California • Chicago, Illinois • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 28, 2026, 1:26 PM EDT